Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients

被引:8
作者
Alsheikh-Ali, Alawi A. [1 ,2 ]
Link, Mark S. [3 ,4 ]
Semsarian, Christopher [5 ,6 ]
Shen, Win-Kuang [7 ]
Estes, N. A. Mark, III [3 ,4 ]
Maron, Martin S. [3 ]
Haas, Tammy S. [8 ]
Formisano, Francesco [9 ]
Boriani, Giuseppe [10 ]
Spirito, Paolo [9 ]
Maron, Barry J. [8 ]
机构
[1] Sheikh Khalifa Med City, Inst Heart & Vasc, Cardiac Arrhythmia Serv, Abu Dhabi, U Arab Emirates
[2] Tufts Univ, Sch Med, Tufts Clin & Translat Sci Inst, Boston, MA 02111 USA
[3] Tufts Med Ctr, Hypertroph Cardiomyopathy Ctr, Boston, MA USA
[4] Tufts Univ, Sch Med, Tufts Med Ctr, New England Cardiac Arrhythmia Ctr, Boston, MA 02111 USA
[5] Univ Sydney, Centenary Inst, Sydney Med Sch, Agnes Ginger Ctr Mol Cardiol, Sydney, NSW 2006, Australia
[6] Royal Prince Alfred Hosp, Dept Cardiol, Sydney, NSW, Australia
[7] Mayo Clin, Div Cardiol, Scottsdale, AZ USA
[8] Minneapolis Heart Inst Fdn, Hypertroph Cardiomyopathy Ctr, Minneapolis, MN USA
[9] Ente Osped Osped Galliera, Div Cardiol, Genoa, Italy
[10] Univ Bologna, Ist Cardiol, Bologna, Italy
基金
英国医学研究理事会;
关键词
Imprantable cardioverter-defibrillator; Ventricular tachycardia; Ventricular fibrillation; Hypertrophic cardiomyopathy; SUDDEN CARDIAC DEATH; CARDIOVERTER-DEFIBRILLATORS; PREVENTION; THERAPY; EFFICACY; STRATEGIES; GUIDELINES;
D O I
10.1016/j.hrthm.2012.10.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Implantable cardioverter-defibrillator (ICD) studies in patients with coronary artery disease report higher risk of ventricular tachycardia/fibrillation (VT/VF) early post-implant, potentially related to local proarrhythmic effects of ICD leads. OBJECTIVE To characterize early and long-term risk of ICD discharge for VT/VF in a large hypertrophic cardiomyopathy (H CM) cohort. METHODS By using HCM multicenter registry data, we compared long-term risk of VT/VF subsequent to an early post-implant period (a priori defined as within 3 months of implant) between patients with or without VT/VF within 3 months after ICD implantation. RESULTS Over a median follow-up of 4.3 years, 109 of 506 (22%) patients with HCM who received ICDs received at least 1 ICD discharge for VT/VF. Risk of first ICD discharge for VT/VF was highest in the first year post-implant (10.8% per person-year; 95% confidence interval 7.9-13.8) and particularly in the first 3 months (17.0% per person-year; 95% confidence interval 9.8-24.3). Patients with early VT/VF (<= 3 months post-implant) were order, and more commonly had secondary prevention ICDs following cardiac arrest or systolic dysfunction (end-stage HCM with ejection fraction <50%). Only 2 of 247 (0.7%) patients with primary prevention ICDs and preserved systolic function had early VT/VF. Patients with VT/VF early post-imprant (<= 3 months) had more than 5-fold higher risk for future VT/VF during long-term follow-up compared with patients without early VT/VF (adjusted hazard ratio 5.4; 95% confidence interval. 2.3-12.6). CONCLUSIONS High-risk patients with HCM and VT/VF early after ICD implantation are particularly prone to subsequent VT/VF throughout follow-up. Early ICD interventions for VT/VF are largely confined to patients with prior cardiac arrest or systolic dysfunction and therefore more likely driven by higher arrhythmic risk rather than read-related proarrhythmia.
引用
收藏
页码:214 / 218
页数:5
相关论文
共 17 条
[11]   Hypertrophic cardiomyopathy - A systematic review [J].
Maron, BJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (10) :1308-1320
[12]   Sudden death in young athletes [J].
Maron, BJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (11) :1064-1075
[13]   Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. [J].
Maron, BJ ;
Shen, WK ;
Link, MS ;
Epstein, AE ;
Almquist, AK ;
Daubert, JP ;
Bardy, GH ;
Favale, S ;
Rea, RF ;
Boriani, G ;
Estes, NAM ;
Spirito, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (06) :365-373
[14]   Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy [J].
Melacini, P. ;
Maron, B. J. ;
Bobbo, F. ;
Basso, C. ;
Tokajuk, B. ;
Zucchetto, M. ;
Thiene, G. ;
Iliceto, S. .
HEART, 2007, 93 (06) :708-710
[15]   ACC/AHA/HRS 2008 guidelines for device-ased therapy of cardiac rhythm abnormalities: Executive summary [J].
Smith, Sidney C., Jr. ;
Epstein, Andrew E. ;
DiMarco, John P. ;
Ellenbogen, Kenneth A. ;
Estes, N. A. Mark ;
Freedman, Roger A. ;
Gettes, Leonard S. ;
Gillinov, A. Marc ;
Gregoratos, Gabriel ;
Hammil, Stephen C. ;
Hayes, David L. ;
Hlatky, Mark A. ;
Newby, L. Kristin ;
Page, Richard L. ;
Schoenfeld, Mark H. ;
Silka, Michael J. ;
Stevenson, Lynne Warner ;
Sweeney, Michael O. .
HEART RHYTHM, 2008, 5 (06) :934-955
[16]   Implantable Cardioverter-Defibrillator in PatientsWith Hypertrophic Cardiomyopathy: Efficacy and Complications of the Therapy in Long-Term Follow-up [J].
Syska, Pawel ;
Przybylski, Andrzej ;
Chojnowska, Lidia ;
Lewandowski, Michal ;
Sterlinski, Maciej ;
Maciag, Aleksander ;
Gepner, Katarzyna ;
Pytkowski, Mariusz ;
Kowalik, Ilona ;
Maczynska-Mazuruk, Renata ;
Ruzyllo, Witold ;
Szwed, Hanna .
JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2010, 21 (08) :883-889
[17]   A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death [J].
Tung, Roderick ;
Zimetbaum, Peter ;
Josephson, Mark E. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (14) :1111-1121